Baidu
map

Diabetes Care:糖尿病可增加慢性心力衰竭患者致死率!

2017-05-05 MedSci MedSci原创

目前已知,糖尿病可能增加患心血管疾病(CVD)风险,同时也增加了致死风险。由于糖尿病患病率在世界范围内上升,且慢性心力衰竭(CHF)在人口老龄化中日益普遍,因此,应及时研究糖尿病1年内不良反应对CHF患者的影响。

目前已知,糖尿病可能增加患心血管疾病(CVD)风险,同时增加致死风险。由于糖尿病患病率在世界范围内上升,且慢性心力衰竭(CHF)在人口老龄化中日益普遍,因此,应及时研究糖尿病1年内不良反应对CHF患者的影响。

该研究前瞻性地评估了在欧洲心脏病学会和心力衰竭协会长期登记的9,428例CHF门诊患者的状况,其中9428例患者来自多国队列。该研究主要评估糖尿病状况是否独立影响1年全因死亡率、CVD死亡风险和心力衰竭恶化(HF)住院率。

结果显示,与无糖尿病患者相比,糖尿病患者(n = 3,440,36.5%)各项累积率分别为:1年全因死亡(9.4%vs 7.2%;调整危险比[HR] 1.28; 95%CI 1.07-1.54),CVD死亡(4.8%vs. 3.8%;调整HR 1.28; 95%CI 0.99-1.66),HF住院率(13.8%vs. 9.3%;调整HR 1.37; 95%CI 1.17-1.60)。可能影响实验结果的因素(年龄,性别,BMI,吸烟,收缩压,估计的肾小球滤过率,血红蛋白,HF病因,左心室射血分数,高血压,他汀类药物使用和先前的中风或慢性阻塞性肺疾病)全部相互独立。在基线时可获得HbA1c测量值的CHF患者(n = 2,567)中,HbA1c水平的升高与1年生存率之间存在显着和独立的关联。

该研究得出结论,糖尿病的存在显着增加了的CHF门诊1年不良临床结果的风险(多种常见危险因素相互独立)。因此,在CHF患者群体中应该考虑对糖尿病进行更有效和个性化的治疗。

原始出处:


本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1941782, encodeId=c3b41941e8227, content=<a href='/topic/show?id=aaa686456e2' target=_blank style='color:#2F92EE;'>#致死率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86456, encryptionId=aaa686456e2, topicName=致死率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0ad8182, createdName=axin009, createdTime=Tue May 23 15:22:00 CST 2017, time=2017-05-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1759959, encodeId=59001e5995986, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Mon Jul 17 13:22:00 CST 2017, time=2017-07-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1637719, encodeId=f422163e7191d, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Fri Mar 16 11:22:00 CST 2018, time=2018-03-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1901631, encodeId=7df81901631ae, content=<a href='/topic/show?id=c097591ed5' target=_blank style='color:#2F92EE;'>#Diabetes#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5917, encryptionId=c097591ed5, topicName=Diabetes)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0045169, createdName=木头人513, createdTime=Fri Jun 09 09:22:00 CST 2017, time=2017-06-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1251781, encodeId=20901251e81bc, content=<a href='/topic/show?id=ac5d5351ea8' target=_blank style='color:#2F92EE;'>#慢性心力衰竭#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53517, encryptionId=ac5d5351ea8, topicName=慢性心力衰竭)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Sat May 06 23:22:00 CST 2017, time=2017-05-06, status=1, ipAttribution=)]
    2017-05-23 axin009
  2. [GetPortalCommentsPageByObjectIdResponse(id=1941782, encodeId=c3b41941e8227, content=<a href='/topic/show?id=aaa686456e2' target=_blank style='color:#2F92EE;'>#致死率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86456, encryptionId=aaa686456e2, topicName=致死率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0ad8182, createdName=axin009, createdTime=Tue May 23 15:22:00 CST 2017, time=2017-05-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1759959, encodeId=59001e5995986, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Mon Jul 17 13:22:00 CST 2017, time=2017-07-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1637719, encodeId=f422163e7191d, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Fri Mar 16 11:22:00 CST 2018, time=2018-03-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1901631, encodeId=7df81901631ae, content=<a href='/topic/show?id=c097591ed5' target=_blank style='color:#2F92EE;'>#Diabetes#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5917, encryptionId=c097591ed5, topicName=Diabetes)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0045169, createdName=木头人513, createdTime=Fri Jun 09 09:22:00 CST 2017, time=2017-06-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1251781, encodeId=20901251e81bc, content=<a href='/topic/show?id=ac5d5351ea8' target=_blank style='color:#2F92EE;'>#慢性心力衰竭#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53517, encryptionId=ac5d5351ea8, topicName=慢性心力衰竭)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Sat May 06 23:22:00 CST 2017, time=2017-05-06, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1941782, encodeId=c3b41941e8227, content=<a href='/topic/show?id=aaa686456e2' target=_blank style='color:#2F92EE;'>#致死率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86456, encryptionId=aaa686456e2, topicName=致死率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0ad8182, createdName=axin009, createdTime=Tue May 23 15:22:00 CST 2017, time=2017-05-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1759959, encodeId=59001e5995986, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Mon Jul 17 13:22:00 CST 2017, time=2017-07-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1637719, encodeId=f422163e7191d, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Fri Mar 16 11:22:00 CST 2018, time=2018-03-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1901631, encodeId=7df81901631ae, content=<a href='/topic/show?id=c097591ed5' target=_blank style='color:#2F92EE;'>#Diabetes#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5917, encryptionId=c097591ed5, topicName=Diabetes)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0045169, createdName=木头人513, createdTime=Fri Jun 09 09:22:00 CST 2017, time=2017-06-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1251781, encodeId=20901251e81bc, content=<a href='/topic/show?id=ac5d5351ea8' target=_blank style='color:#2F92EE;'>#慢性心力衰竭#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53517, encryptionId=ac5d5351ea8, topicName=慢性心力衰竭)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Sat May 06 23:22:00 CST 2017, time=2017-05-06, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1941782, encodeId=c3b41941e8227, content=<a href='/topic/show?id=aaa686456e2' target=_blank style='color:#2F92EE;'>#致死率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86456, encryptionId=aaa686456e2, topicName=致死率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0ad8182, createdName=axin009, createdTime=Tue May 23 15:22:00 CST 2017, time=2017-05-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1759959, encodeId=59001e5995986, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Mon Jul 17 13:22:00 CST 2017, time=2017-07-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1637719, encodeId=f422163e7191d, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Fri Mar 16 11:22:00 CST 2018, time=2018-03-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1901631, encodeId=7df81901631ae, content=<a href='/topic/show?id=c097591ed5' target=_blank style='color:#2F92EE;'>#Diabetes#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5917, encryptionId=c097591ed5, topicName=Diabetes)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0045169, createdName=木头人513, createdTime=Fri Jun 09 09:22:00 CST 2017, time=2017-06-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1251781, encodeId=20901251e81bc, content=<a href='/topic/show?id=ac5d5351ea8' target=_blank style='color:#2F92EE;'>#慢性心力衰竭#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53517, encryptionId=ac5d5351ea8, topicName=慢性心力衰竭)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Sat May 06 23:22:00 CST 2017, time=2017-05-06, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1941782, encodeId=c3b41941e8227, content=<a href='/topic/show?id=aaa686456e2' target=_blank style='color:#2F92EE;'>#致死率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86456, encryptionId=aaa686456e2, topicName=致死率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0ad8182, createdName=axin009, createdTime=Tue May 23 15:22:00 CST 2017, time=2017-05-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1759959, encodeId=59001e5995986, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Mon Jul 17 13:22:00 CST 2017, time=2017-07-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1637719, encodeId=f422163e7191d, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Fri Mar 16 11:22:00 CST 2018, time=2018-03-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1901631, encodeId=7df81901631ae, content=<a href='/topic/show?id=c097591ed5' target=_blank style='color:#2F92EE;'>#Diabetes#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5917, encryptionId=c097591ed5, topicName=Diabetes)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0045169, createdName=木头人513, createdTime=Fri Jun 09 09:22:00 CST 2017, time=2017-06-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1251781, encodeId=20901251e81bc, content=<a href='/topic/show?id=ac5d5351ea8' target=_blank style='color:#2F92EE;'>#慢性心力衰竭#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53517, encryptionId=ac5d5351ea8, topicName=慢性心力衰竭)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Sat May 06 23:22:00 CST 2017, time=2017-05-06, status=1, ipAttribution=)]

相关资讯

Cell Metabolism:新型AMPK激活剂具有治疗糖尿病的潜力

在灵长类食蟹猴(cynomolgus monkeys)中使用PF-739的研究证实了其激活AMPK降低血液中葡萄糖含量,增强骨骼肌中吸收葡萄糖能力。因此这一AMPK激活剂具有巨大潜力成为治疗糖尿病患者的潜在治疗方法

Diabetes Care:心脏代谢疾病分期预测通过减肥预防2型糖尿病的有效性

近期,一项发表在杂志Diabetes Care上的研究评估了药物辅助减肥以预防糖尿病的能力,并评估了基线心脏代谢疾病分期(CMDS)评分的功能。研究者们将3,040名超重和肥胖受试者的数据汇总在三项随机对照试验中-CONQUER,EQUIP和SEQUEL,以评估苯丁胺/托吡酯延长释放(ER)对减肥的疗效和安全性。在这些双盲III期试验中,超重/肥胖成年患者接受生活方式的干预治疗,随机分配到安慰剂对

没有想不到:糖尿病治疗及检测刮起“智能风”

知道吗?糖尿病治疗及检测也刮起了“智能风”。

Sci Rep:糖尿病和神经胶质瘤之间存在逆关联!

神经胶质瘤是一种异质性原发性脑肿瘤,目前没有可以长期存活的治疗方法。诊断为胶质母细胞瘤的患者平均生存期14个月。症状通常仅在诊断前三个月才发生;因此,重要的是在症状发作前确定临床前肿瘤的指标。

专题:精华指南在手,糖尿病防控不再难

糖尿病是一组以高血糖为特征的代谢性疾病。糖尿病常见并发症包 括卒中、心肌梗死、视网膜病变、糖尿病足、糖尿病肾病肾脏衰竭等。在欧美国家,糖尿病视网膜病变和糖尿病肾病分别是首位致盲和致终末期肾病的原因,尽早科学开展综合治疗、规范管理、并发症的监测和及早干预,有利于减少、延缓和控制糖尿病的并发症,使得大多数糖尿病患者可以享受正常生活。梅斯小编整理糖尿病相关指南,供大家参考! 一、预 防 1、

Sci Rep:血糖和神经胶质瘤之间意想不到的联系

神经胶质瘤是一种异质性原发性脑肿瘤,目前没有可以长期存活的治疗方法。诊断为胶质母细胞瘤的患者平均生存期14个月。症状通常仅在诊断前三个月才发生;因此,重要的是在症状发作前确定临床前肿瘤的指标。

Baidu
map
Baidu
map
Baidu
map